| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| D Kaufe. Beyond the cholinergic hypothesis: the effect of metrifonate and other cholinesterase inhibitors on neuropsychiatric symptoms in Alzheimer's disease. Dementia and geriatric cognitive disorders. vol 9 Suppl 2. 1998-11-06. PMID:9718229. |
preliminary studies suggest that non-cognitive behavioural and personality alterations in alzheimer's disease may benefit from agents which inhibit central acetylcholinesterase (ache). |
1998-11-06 |
2023-08-12 |
Not clear |
| A Rampa, A Bisi, P Valenti, M Recanatini, A Cavalli, V Andrisano, V Cavrini, L Fin, A Buriani, P Giust. Acetylcholinesterase inhibitors: synthesis and structure-activity relationships of omega-[N-methyl-N-(3-alkylcarbamoyloxyphenyl)- methyl]aminoalkoxyheteroaryl derivatives. Journal of medicinal chemistry. vol 41. issue 21. 1998-11-03. PMID:9767635. |
acetylcholinesterase (ache) inhibitors are one of the most actively investigated classes of compounds in the search for an effective treatment of alzheimer's disease. |
1998-11-03 |
2023-08-12 |
rat |
| C Allal, E Lazartigues, M A Tran, C Brefel-Courbon, C Gharib, J L Montastruc, O Rasco. Central cardiovascular effects of tacrine in the conscious dog: a role for catecholamines and vasopressin release. European journal of pharmacology. vol 348. issue 2-3. 1998-10-26. PMID:9652334. |
the aim of this study was to investigate the effects of tacrine, an acetylcholinesterase inhibitor which has been reported to have therapeutic potential in alzheimer's disease, on blood pressure and two vasopressor systems (sympathetic and vasopressinergic) in beagle dogs. |
1998-10-26 |
2023-08-12 |
dog |
| L E Tune, T Sunderlan. New cholinergic therapies: treatment tools for the psychiatrist. The Journal of clinical psychiatry. vol 59 Suppl 13. 1998-10-20. PMID:9771828. |
the focus is on pivotal articles investigating the role of cholinergic augmentation strategies, including precursor loading and acetylcholinesterase (ache) inhibitors, in the management of cognitive and noncognitive symptoms of alzheimer's disease. |
1998-10-20 |
2023-08-12 |
Not clear |
| F H Calderón, R von Bernhardi, G De Ferrari, S Luza, R Aldunate, N C Inestros. Toxic effects of acetylcholinesterase on neuronal and glial-like cells in vitro. Molecular psychiatry. vol 3. issue 3. 1998-10-08. PMID:9672900. |
acetylcholinesterase (ache), the enzyme involved in the hydrolysis of the neurotransmitter acetylcholine, has been implicated in non-cholinergic actions which may play a role in neurodegenerative diseases such as alzheimer's disease. |
1998-10-08 |
2023-08-12 |
Not clear |
| T Mant, W M Troetel, B P Imbimb. Maximum tolerated dose and pharmacodynamics of eptastigmine in elderly healthy volunteers. Journal of clinical pharmacology. vol 38. issue 7. 1998-10-05. PMID:9702845. |
eptastigmine is a new acetylcholinesterase (ache) inhibitor currently under development for the symptomatic treatment of alzheimer disease. |
1998-10-05 |
2023-08-12 |
human |
| S I Gracon, M J Knapp, W G Berghoff, M Pierce, R DeJong, S J Lobbestael, J Symons, S L Dombey, F A Luscombe, D Kraeme. Safety of tacrine: clinical trials, treatment IND, and postmarketing experience. Alzheimer disease and associated disorders. vol 12. issue 2. 1998-09-08. PMID:9651138. |
the safety of tacrine (cognex), a centrally active, reversible acetylcholinesterase inhibitor approved in 1993 for the treatment of mild to moderate dementia of the alzheimer type, was evaluated in 2,706 patients with alzheimer disease (ad) in clinical trials and in 9861 patients with ad in a treatment investigational new drug (tind) program. |
1998-09-08 |
2023-08-12 |
Not clear |
| B A Duncan, A P Siega. Early diagnosis and management of Alzheimer's disease. The Journal of clinical psychiatry. vol 59 Suppl 9. 1998-08-28. PMID:9720482. |
there have been several recent pharmacologic advances in the treatment of alzheimer's disease, including the development of acetylcholinesterase inhibitors. |
1998-08-28 |
2023-08-12 |
Not clear |
| P N Tario. Evaluating response to metrifonate. The Journal of clinical psychiatry. vol 59 Suppl 9. 1998-08-28. PMID:9720485. |
metrifonate, administered orally to patients with probable alzheimer's disease in a once-daily dose, readily enters the brain and inhibits brain acetylcholinesterase (ache) activity in a dose-dependent fashion. |
1998-08-28 |
2023-08-12 |
Not clear |
| G Sberna, J Sáez-Valero, Q X Li, C Czech, K Beyreuther, C L Masters, C A McLean, D H Smal. Acetylcholinesterase is increased in the brains of transgenic mice expressing the C-terminal fragment (CT100) of the beta-amyloid protein precursor of Alzheimer's disease. Journal of neurochemistry. vol 71. issue 2. 1998-08-19. PMID:9681463. |
acetylcholinesterase is increased in the brains of transgenic mice expressing the c-terminal fragment (ct100) of the beta-amyloid protein precursor of alzheimer's disease. |
1998-08-19 |
2023-08-12 |
mouse |
| G Sberna, J Sáez-Valero, Q X Li, C Czech, K Beyreuther, C L Masters, C A McLean, D H Smal. Acetylcholinesterase is increased in the brains of transgenic mice expressing the C-terminal fragment (CT100) of the beta-amyloid protein precursor of Alzheimer's disease. Journal of neurochemistry. vol 71. issue 2. 1998-08-19. PMID:9681463. |
acetylcholinesterase (ache) expression is markedly affected in alzheimer's disease (ad). |
1998-08-19 |
2023-08-12 |
mouse |
| Z Henderson, P S Harrison, E Jagger, J H Beeb. Density of choline acetyltransferase-immunoreactive terminals in the rat dentate gyrus after entorhinal cortex lesions: a quantitative light microscope study. Experimental neurology. vol 152. issue 1. 1998-08-17. PMID:9682012. |
lesion of the entorhinal cortex in the adult rat is a model for alzheimer's disease and produces a marked increase in acetylcholinesterase (ache) activity in the outer molecular layer (oml) of the dentate gyrus. |
1998-08-17 |
2023-08-12 |
rat |
| G Benzi, A Morett. Is there a rationale for the use of acetylcholinesterase inhibitors in the therapy of Alzheimer's disease? European journal of pharmacology. vol 346. issue 1. 1998-08-04. PMID:9617746. |
is there a rationale for the use of acetylcholinesterase inhibitors in the therapy of alzheimer's disease? |
1998-08-04 |
2023-08-12 |
Not clear |
| G Benzi, A Morett. Is there a rationale for the use of acetylcholinesterase inhibitors in the therapy of Alzheimer's disease? European journal of pharmacology. vol 346. issue 1. 1998-08-04. PMID:9617746. |
among these strategies, the one based on acetylcholinesterase inhibition is currently the most extensively developed for the therapy of alzheimer's disease. |
1998-08-04 |
2023-08-12 |
Not clear |
| G Benzi, A Morett. Is there a rationale for the use of acetylcholinesterase inhibitors in the therapy of Alzheimer's disease? European journal of pharmacology. vol 346. issue 1. 1998-08-04. PMID:9617746. |
this review, therefore, focuses on the complex nature of the acetylcholine system, the alterations of acetylcholinesterase and muscarinic receptor signal transduction in alzheimer's disease, and the involvement of other neurotransmitters. |
1998-08-04 |
2023-08-12 |
Not clear |
| P Taylo. Development of acetylcholinesterase inhibitors in the therapy of Alzheimer's disease. Neurology. vol 51. issue 1 Suppl 1. 1998-07-30. PMID:9674760. |
development of acetylcholinesterase inhibitors in the therapy of alzheimer's disease. |
1998-07-30 |
2023-08-12 |
human |
| A Badia, J E Baños, P Camps, J Contreras, D M Görbig, D Muñoz-Torrero, M Simón, N M Viva. Synthesis and evaluation of tacrine-huperzine A hybrids as acetylcholinesterase inhibitors of potential interest for the treatment of Alzheimer's disease. Bioorganic & medicinal chemistry. vol 6. issue 4. 1998-07-23. PMID:9597187. |
synthesis and evaluation of tacrine-huperzine a hybrids as acetylcholinesterase inhibitors of potential interest for the treatment of alzheimer's disease. |
1998-07-23 |
2023-08-12 |
Not clear |
| N R Cutler, R J Polinsky, J J Sramek, A Enz, S S Jhee, L Mancione, J Hourani, P Zolnoun. Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer's disease. Acta neurologica Scandinavica. vol 97. issue 4. 1998-06-23. PMID:9576639. |
dose-dependent csf acetylcholinesterase inhibition by sdz ena 713 in alzheimer's disease. |
1998-06-23 |
2023-08-12 |
Not clear |
| N R Cutler, R J Polinsky, J J Sramek, A Enz, S S Jhee, L Mancione, J Hourani, P Zolnoun. Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer's disease. Acta neurologica Scandinavica. vol 97. issue 4. 1998-06-23. PMID:9576639. |
this study evaluates the activity of sdz ena 713, a centrally-selective acetylcholinesterase (ache) inhibitor, in the cerebral spinal fluid (csf) of patients with alzheimer's disease (ad), and its relationship to central and peripheral pharmacokinetic parameters. |
1998-06-23 |
2023-08-12 |
Not clear |
| J L Cummings, P A Cyrus, F Bieber, J Mas, J Orazem, B Gulansk. Metrifonate treatment of the cognitive deficits of Alzheimer's disease. Metrifonate Study Group. Neurology. vol 50. issue 5. 1998-06-08. PMID:9595966. |
the efficacy and safety of metrifonate, an acetylcholinesterase inhibitor, was evaluated clinically in patients diagnosed with mild to moderate alzheimer's disease (ad). |
1998-06-08 |
2023-08-12 |
Not clear |